期刊文献+

丁螺环酮对5-HT再摄取抑制剂类抗抑郁药物的增效作用 被引量:1

下载PDF
导出
摘要 目的探讨丁螺环酮对5-HT再摄取抑制剂类抗抑郁药物的增效作用。方法 100例首诊均符合广泛性焦虑诊断标准的患者随机分成治疗组和对照组各50例,对照组单纯给予5-HT再摄取抑制药物,按药物说明书给予常规逐渐加量治疗;治疗组采用丁螺环酮联合5-HT再摄取抑制剂类抗抑郁药物治疗,入组即刻及治疗后第1、2、4周分别用汉密顿焦虑量表和不良反应量表评定丁螺环酮的疗效及安全性。结果治疗第1周和第2周HAMA评分与对照组比较有显著性差异(均P〈0.01),第4周两组HAMA评分无显著性差异(P〉0.05),治疗效果达到相同水平;两组不良反应发生率无显著性差异(P〉0.05),结论丁螺环酮15~30mg/d的常规剂量可以作为5-HT再摄取抑制剂类抗抑郁药物的增效剂使用,在临床上可以迅速缓解患者的焦虑症状,并且其不良反应轻微。
出处 《浙江实用医学》 2012年第6期417-418,共2页 Zhejiang Practical Medicine
  • 相关文献

参考文献5

二级参考文献17

  • 1刘月芬,李恩泽.我院2001~2002年抗抑郁药用药分析[J].齐鲁医学杂志,2004,19(4):343-344. 被引量:6
  • 2梅其一 王晓龙.丁螺环酮开放治疗焦虑症19例临床分析[J].临床精神医学杂志,1998,6:332-332.
  • 3夏友春摘译.丁螺环酮对抗抑郁剂的增效作用[J].国外医学:精神病学分册,1992,1:47-47.
  • 4Robinson DS.Clinical effects of 5-HT1A partial agonists in depression:Acomposite analysis of buspirone in he treatment of depression [ J]. J Chin Psychopharmacology, 1990,10: 67.
  • 5Stahi SM. Essential psychopharmacology[ M]. Second Edition. Cambridge University Press,200-273.
  • 6Evangelos C. Buspirone argumentation of antidepressant therapy [ M ]. J Chin psychiatry, 1998,59:466.
  • 7ROBINSON D S.Clinical effects of the 5-HT1A partial agonists in depression:a composite analysis in the treatment of depression[J].J Clin Psychopharmacol,1990,10:67-76.
  • 8RICKELS K.Buspirone in major depression:a controlled study[J].J Clin Psychiatry,1991,52(1):34-38.
  • 9STAHL.SM Essential Psychopharmacology[M].2nd.Newyork:Cambridge University Press,2000:273-278.
  • 10BATTISTAC D E,SOFUOGLU M,SCHATZBERG A F.Serotonergic synergism:the risk and benefits of combining the selective serotomin reuptake inhibitors with other serotonergic drugs[J].Biol Psychiatry,1998,44:34-39.

共引文献99

同被引文献38

  • 1李一云,季建林.文拉法辛与米氮平治疗抑郁症的临床比较分析[J].上海精神医学,2003,15(6):358-360. 被引量:23
  • 2喻东山.内科中的惊恐障碍[J].临床精神医学杂志,2007,17(5):354-355. 被引量:7
  • 3Eaton WW, Kessler RC, Wittchen HU, et al. Panic and panic disorder in the United State [ J]. Am J Psychiatry, 1994,151 (3) :413 -420.
  • 4Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age - of - onset distributions of DSM - IV disorders in theNational Comorbidity Survey Replication [ J]. Arch Gen Psychi- atry, 2005, 62(6):593-602.
  • 5Simon NM, Fischmann D. The implications of medical and psy- chiatric comorbidity with panic disorder [ J]. J Clin Psychiatry, 2005,66( Suppl 4) :8 - 15.
  • 6Waiters K, Rait G, Petersen I. Panic disorder and risk of new onset coronary heart disease, acute myocardial infarction, and cardiac mortality: cohort study using the general practice re- search database [J]. European Heart Journal, 2008,29(24) : 2 981 - 2 988.
  • 7Henkel V, Seemuller F, Obermeier M, et al. Does early im- provement triggered by antidepressants predict response/remis- sion? Analysis of data fore a naturalistic study on a large sample of inpatients with major depression [J]. J Affect Disord, 2009, 115(3) :439 -449.
  • 8Gourion D, Galinowski A, Baraille L, et al. Switch antidepres- sants: when.? How? Why? [J]. Encephale, 2011, 37 (Suppl 1) :S50 -S57.
  • 9WHO. The world health report 2001 - Mental health: new un- derstanding, new hope [ EB/OL] . http://www, who. int/ whr/ 2001/ err/.
  • 10Seitz DP, Campbell RJ, Bell CM, et al. Short -term exposure to antidepressant drug and risks of acute angle - closure glauco- ma among older adults [ J ] . J Clin Psychopharm, 2012. 32 (3) :403 -407.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部